Compare BTZ & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTZ | NNNN |
|---|---|---|
| Founded | 2006 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 998.6M | 1.5B |
| IPO Year | N/A | N/A |
| Metric | BTZ | NNNN |
|---|---|---|
| Price | $10.15 | $21.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 286.6K | 39.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 9.40% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.41 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $7.25 | $446.57 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.54 | $5.91 |
| 52 Week High | $11.18 | $55.65 |
| Indicator | BTZ | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 20.88 | 43.49 |
| Support Level | N/A | $19.25 |
| Resistance Level | $10.84 | $31.44 |
| Average True Range (ATR) | 0.09 | 2.30 |
| MACD | -0.05 | -0.15 |
| Stochastic Oscillator | 3.31 | 13.32 |
Blackrock Credit Allocation Income Trust is a diversified, closed-end Trust engaged in providing investment advisory and risk management solutions. Its investment objective is to seek current income, current gains, and capital appreciation. The company invests under normal market conditions, at least 80% of its assets in credit-related securities, including, but not limited to, investment-grade corporate bonds, high-yields, bank loans, preferred securities or convertible bonds, or derivatives with economic characteristics similar to these credit-related securities.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.